NCT06361199View on ClinicalTrials.gov

Proximod Pharmacokinetics in Healthy Subjects and Patients With Rheumatoid Arthritis

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 16, 2021

Primary Completion Date

February 16, 2022

Study Completion Date

October 8, 2023

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Proximod

Multiple-dose to establish the safety and PK profile in both healthy subjects and patients with rheumatoid arthritis

DRUG

Placebo

Placebo controlled

Trial Locations (1)

Unknown

The first hospital of Jilin University, Changchun

Sponsors

Lead Sponsor

Longevity Inc.
All Listed Sponsors
lead

Longevity Inc.

INDUSTRY

NCT06361199 - Proximod Pharmacokinetics in Healthy Subjects and Patients With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter